A head-to-head study comparing five serological assays for SARS-CoV-2 antibodies showed that a commercial immunoassay by Siemens and a novel ELISA* test developed by the University of Oxford could achieve the desired sensitivity and specificity without further optimization — providing reassurance for their use.
As high as 40 percent of the healthcare workers (HCWs) infected with COVID-19 were asymptomatic, raising concerns on silent transmission in the healthcare settings, according to a systematic review and meta-analysis released during ECCVID 2020.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.